Anticonvulsants for Neuropathic Pain

Mechanism of action

The common thread is the reduction of ectopic neuronal firing — an injured nerve generates spontaneous impulses and responds excessively to stimuli, and that hyperexcitability is the substrate of neuropathic pain. Each class acts from a different angle; the result converges: lower excitability, less pain.

Gabapentinoids bind to the alpha-2-delta subunit of voltage-gated calcium channels at presynaptic terminals, reducing Ca2+ influx and release of excitatory neurotransmitters (glutamate, substance P, CGRP). Despite the suggestive name, they do not act directly on GABA. Carbamazepine and oxcarbazepine stabilize voltage-gated sodium channels in the inactivated state, reducing high-frequency firing — the pattern of ectopic discharge in trigeminal neuralgia, where NNT around 2-3 is one of the best in pain medicine.

Topiramate combines mechanisms (Na+, GABA, AMPA/kainate, carbonic anhydrase) — these support migraine prophylaxis and explain the cognitive effects. Lamotrigine blocks Na+ and modulates glutamate — evidence in pain is smaller, with selected use in central pain (post-stroke, spinal cord injury) when other options fail.

Scientific evidence

The evidence is heterogeneous — ranging from remarkably high (carbamazepine in trigeminal neuralgia) to modest (pregabalin in fibromyalgia) and to negative or absent in non-neuropathic pain. Treating "anticonvulsants" as a homogeneous block is the most common conceptual error.

The EFNS guideline (Cruccu et al., Eur J Neurol 2008, updated 2019) consolidated carbamazepine as first-line in trigeminal neuralgia; oxcarbazepine is an alternative with comparable evidence and a better tolerability profile. The Cochrane reviews by Wiffen et al. (2017) for gabapentin and Derry et al. (2019) for pregabalin synthesize trials in neuropathic pain and establish NNT around 6-8 for clinically relevant relief — a modest but reproducible level. In neuropathic pain broadly, the guideline by Finnerup et al. (Lancet Neurology 2015) positions gabapentinoids alongside tricyclics and SNRIs as first-line — the choice depends on comorbidities and tolerance.

In migraine prophylaxis, topiramate has consistent evidence in meta-analyses (Silberstein and subsequent guidelines) — reduction of frequency and intensity of attacks at doses of 50-100 mg/day, typically as an alternative to beta-blockers or amitriptyline. In fibromyalgia, pregabalin is FDA-approved; the effect is modest and the recommendation in guidelines (EULAR) positions it as an option, not as first-line — where amitriptyline, duloxetine and structured exercise typically lead.

On the critical side: the use of gabapentinoids in non-neuropathic pain (chronic low back pain without radiculopathy, generic musculoskeletal pain) has grown enormously without scientific support — well-designed trials in nonspecific low back pain are negative. Data on misuse and abuse of pregabalin are documented (Bonnet et al., Eur Neuropsychopharmacology 2017), especially in vulnerable populations. In some countries (United Kingdom), gabapentinoids have been reclassified as controlled substances.

Indications

Evidence-based indications are condition- specific — not "anticonvulsant for any chronic pain". Choosing the right agent for the right condition is what separates rational use from generic prescribing, and the recommendations follow guidelines with more than a decade of consolidation.

How they are used

Three principles guide rational use: slow titration from a low dose, time to effect of 1-4 weeks, and mandatory gradual discontinuation. Abrupt interruption of carbamazepine may precipitate a seizure even in non-epileptic patients; that of gabapentinoids causes pain rebound and anxiety. Patient education on expectations and discontinuation is itself a clinical intervention.

Slow titration of anticonvulsants: gabapentin 300mg at night, increased every two weeks; carbamazepine 200mg twice daily, escalated progressively

Fig. · placeholder

Anticonvulsants used in pain — by generic name

Availability is broad and most agents have well-established generics. Generic gabapentin is one of the best cost-benefit options in neuropathy — widely available in public health systems. Pregabalin is more expensive with variable insurance coverage. Carbamazepine is generally available based on its epilepsy history. All require a prescription. In some countries (United Kingdom), gabapentinoids are controlled substances due to abuse potential; classification varies elsewhere.

Practical note: the most common error in prescribing gabapentin is underdosing — 300 mg at night as a fixed dose is rarely effective. The analgesic dose typically starts at 900-1200 mg/day in 3 doses and can reach 3600 mg/day. Pregabalin has more convenient dosing (twice daily) and more predictable bioavailability — which justifies its choice in low adherence or in gabapentin failures.

Dosing, interactions and special populations

Older adults. Gabapentin and pregabalin are on the Beers list due to risk of sedation, dizziness and falls. Start at one quarter of the adult dose, adjust by clearance < 60 mL/min. Carbamazepine in older adults carries an increased risk of hyponatremia.

Renal impairment. Gabapentinoids are renally excreted — adjustment is mandatory by clearance; relative contraindication in dialysis (or small doses with post-dialysis replacement). Topiramate also requires adjustment. Carbamazepine has hepatic metabolism — less affected.

Pregnant patients. Carbamazepine and valproic acid are teratogenic (neural tube defects, especially in the first trimester); topiramate is associated with cleft palate. When an anticonvulsant is necessary, gabapentin and pregabalin are preferable — shared decision with the obstetrician and neurology team, with high-dose folic acid.

Lactating mothers. Data are variable; gabapentin is acceptable at usual doses; lamotrigine has greater excretion; carbamazepine is traditionally accepted. Discuss with the obstetrician and pediatrician.

Children and adolescents. Use in pain is off-label in most indications and requires specialist prescribing. Pediatric neuropathic pain is rare and the threshold for pharmacotherapy is higher.

Adverse effects, risks and contraindications

The risk profile of anticonvulsants in pain is molecule-specific — generalizations about "anticonvulsants" hide clinically relevant differences. Most adverse effects are dose-dependent and improve with slow titration, but some require monitoring or specific attention.

Important contraindications. Gabapentinoids: hypersensitivity; caution in advanced renal impairment (mandatory adjustment). Carbamazepine: hypersensitivity to carbamazepine/oxcarbazepine/tricyclics; bone marrow suppression; porphyria; atrioventricular block; concomitant use of MAOIs; HLA-B*1502 positive in at-risk populations (strong recommendation to avoid). Topiramate: pregnancy (risk of cleft palate), recurrent nephrolithiasis. Lamotrigine: hypersensitivity; cautious use with valproate.

Limitations and what is still unknown

Anticonvulsants in pain face a peculiar tension: in trigeminal neuralgia, carbamazepine is one of the greatest successes in pain medicine; in chronic low back pain, the use of gabapentinoids has grown globally despite weak or absent evidence. Understanding this heterogeneity — and the role of off-label use — is a central part of an honest discussion with the patient.

Evidence Gaps

Inflated prescribing of gabapentinoids globally. Between 2002 and 2015, use multiplied in several countries — in large part for indications outside the evidence(nonspecific low back pain, sciatica without focal déficit, generic musculoskeletal pain). Well-designed trials in those indications are negative.

Data on abuse and recreational use are real. Bonnet et al. (Eur Neuropsychopharmacology 2017) consolidated evidence of pregabalin abuse potential, especially in populations with a history of chemical dependence. The United Kingdom reclassified gabapentinoids as controlled substances in 2019; many other countries have not yet adopted similar classification — but prudence is the same, especially in combination with opioids.

Carbamazepine in trigeminal neuralgia: first-line but difficult. Notable efficacy, challenging tolerability — hyponatremia, sedation, interactions, Stevens-Johnson in HLA-B*1502. Many switch to oxcarbazepine or migrate to alternatives (baclofen, gabapentin, decompression surgery). Alternatives with equivalent first-line evidence do not exist.

Long-term data are limited. Trials cover 8-12 weeks. Chronic use over years, discontinuation, prolonged cognitive effect in older adults and combinations remain partial áreas — periodic reassessment is the reasonable standard.

Relationship with medical acupuncture

Anticonvulsants and medical acupuncture act through distinct mechanisms — the former on ion channels and neuronal excitability; acupuncture on local and central neuromodulation (PAG, endogenous opioids, autonomic modulation). No pharmacological interactions are described, which allows combination in a plan coordinated by the physician — in patients with intolerable adverse effects (sedation, cognitive effects, edema, weight gain), the addition of acupuncture may contribute to pain management, while any dose adjustment or substitution of the anticonvulsant is the physician's decision and follows gradual tapering. Detailed comparison in Gabapentinoids in Chronic Pain.

When to seek medical care

The use of an anticonvulsant in pain always involves medical follow-up — for the class itself, for titration, for interactions and for at-risk populations. Some signs require early contact and others constitute a clinical emergency.